3 more Indians in UAE lose jobs for 'Islamobhobic' social media posts

Interview with Martin E. Franklin, PhD, author of Cognitive Behavior Therapy Augmentation of Pharmacotherapy in Pediatric Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study II (POTS II) Randomized Controlled Trial

Interview with Pim A. de Jong, MD, PhD, author of Identification of Chronic Obstructive Pulmonary Disease in Lung Cancer Screening Computed Tomographic Scans

Interview with Ferran Barbé, MD, author of Effect of Continuous Positive Airway Pressure on the Incidence of Hypertension and Cardiovascular Events in Nonsleepy Patients With Obstructive Sleep Apnea: A Randomized Controlled Trial

Interview with Jonas Rutishauser, MD, author of Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: The REDUCE Randomized Clinical Trial

Interview with Karen A. D'Silva, MD, MS, author of Does This Man With Lower Urinary Tract Symptoms Have Bladder Outlet Obstruction? The Rational Clinical Examination: A Systematic Review

Interview with Andrea S. Gershon, MD, MSc, author of Combination Long-Acting β-Agonists and Inhaled Corticosteroids Compared With Long-Acting β-Agonists Alone in Older Adults With Chronic Obstructive Pulmonary Disease

Interview with Elizabeth A Howell, MD, MPP, author of Durability of Benefits of an Outpatient Antimicrobial Stewardship Intervention After Discontinuation of Audit and Feedback

Interview with Thomas M. Maddox, MD, MSc, author of Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction

Interview with William R. Phillips, MD, MPH, author of Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Recommendation Statement

Interview with Alex H. Krist, MD, MPH, Task Force member and co-author of Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement

Barker Library - TL725.3.M2 B467 2019

Online Resource

Barker Library - HE9797.4.W4 S95 2019

Rotch Library - HT169.I52 B6884 2015

Rotch Library - DS80.4.C35 2017

Rotch Library - NA1478.T45 G39 2018

Rotch Library -

With the emergence of coronavirus disease 2019 (COVID-19) as a global pandemic, individuals with preexisting chronic health conditions such as hypertension, diabetes, and cardiovascular disease have been identified as particularly vulnerable. These patients are also more likely than the general population to be taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 gains entry into cells via binding to the angiotensin-converting enzyme 2 (ACE2) receptor, concerns have been raised that these therapies might facilitate the transmission of the virus or affect outcomes adversely. Given that ACEI and ARB therapies are known to provide benefit for the underlying conditions treated, stopping ACEI/ARB therapy carries risks. Moreover, local inactivation of the renin-angiotensin-aldosterone system may have protective effects against the development and progression of acute lung failure. In the absence of clinical evidence of benefit or risk of ACEIs/ARBs, current societal statements recommend against discontinuing these drugs other than for standard clinical indications. Robust clinical data are needed to clarify the effect of ACEIs/ARBs on SARS-CoV-2 infection.

Hobson, Fred C, 1943-

Robson, Colin, author

Barker Library - PN6728.D6445 D56 2018